61 results
424B5
ANNX
Annexon Inc
5 Apr 24
Prospectus supplement for primary offering
4:07pm
and the classical cascade early in the disease process may act to rapidly prevent complement-mediated nerve damage and irreversible neurological disability
8-K
EX-99.1
820 b7enkvbtj0wj3z9
4 Mar 24
Regulation FD Disclosure
5:25pm
424B5
f37w1txotjfl
21 Dec 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
91mv20wga2
11 Oct 23
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal
4:44pm
8-K
EX-99.2
dw1m2vy4g2ngezyjs
8 Jul 22
Annexon Announces $130 Million Private Placement Financing
5:19pm
8-K
EX-99.1
qrp5a
9 May 22
Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results
4:20pm
POS AM
cd6pns 1f1j6
1 Mar 22
Prospectus update (post-effective amendment)
6:38pm